@misc{oai:repo.qst.go.jp:00065005,
 author = {Akamatsu, Hiroko and Imai, Reiko and Kamada, Tadashi and 赤松 妃呂子 and 今井 礼子 and 鎌田 正},
 month = {May},
 note = {Purpose: The results of carbon ion radiotherapy for unresectable sacral chordoma were summarized to evaluate efficacy and safety. 
Patients and Methods: We performed a retrospective analysis on 175 patients with unresectable sacral chordomas treated with carbon ion radiotherapy between June 1996 and February 2012. All of the patients in this study presented without prior treatment. The applied carbon ion dose ranged from 64.0 GyE to 73.6 GyE (Gray equivalent, median 70.4 GyE) in a total of 16 fixed fractions over four weeks. 
Results: The median age of the patients was 67 ranging from 26 to 87. The study group consisted of 55 females and 120 males. The cranial extension of tumor was S2 or higher level in 70% of the patients. The median clinical target volume was 344 cm3. The median follow up period was 59 months. Five-year overall survival and 5-year local control rates were 82% and 79%, respectively. After carbon ion radiotherapy, the ambulatory in 97% of the patients remained with or without supportive devices. Two patients experienced severe skin/soft tissue complications requiring skin grafts.
Conclusion: CIRT appears effective and safe in the management of patients with unresectable sacral chordoma and offers a promising alternative to surgery., Heavy Ion in Therapy and Space Radiation Symposium 2013(HITSRS2013)},
 title = {Carbon Ion Radiotherapy for Unresectable Sacral Chordoma},
 year = {2013}
}